Şunu mu demek istediniz:
harm » arm (Aramayı Genişlet), farm (Aramayı Genişlet), hard (Aramayı Genişlet)
evolves. » evolved. (Aramayı Genişlet), evolve. (Aramayı Genişlet)
revolve. » revolves. (Aramayı Genişlet), evolve. (Aramayı Genişlet)
harm » arm (Aramayı Genişlet), farm (Aramayı Genişlet), hard (Aramayı Genişlet)
evolves. » evolved. (Aramayı Genişlet), evolve. (Aramayı Genişlet)
revolve. » revolves. (Aramayı Genişlet), evolve. (Aramayı Genişlet)
-
121
-
122
The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>.
Baskı/Yayın Bilgisi 2022Konular: -
123
The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium.
Baskı/Yayın Bilgisi 2022Konular: -
124
Aggregated results for reported benefits and harms, stratified by leaflets and booklets.
Baskı/Yayın Bilgisi 2014“…<p>The figure indicates whether a leaflet contains <u>any</u> information on the benefits of CRC screening a) in general or specifically for b) colonoscopy or c) the FOBT, and whether it contains any information on the d) general and e) specific harms of colonoscopy. To be rated positive for harms, it was not sufficient if the only information about possible harms referred to pain, stating incorrectly that there is no pain involved.…”
-
125
Trend of total annual payments from pharmaceutical companies to breast cancer specialists in Japan, 2016–2019.
Baskı/Yayın Bilgisi 2024Konular: -
126
Overview of pharmaceutical payments to breast cancer specialists in Japan, 2016–2019.
Baskı/Yayın Bilgisi 2024Konular: -
127
-
128
Total payments and annual changes for top 10 pharmaceutical companies to breast cancer specialists in Japan, 2016–2019.
Baskı/Yayın Bilgisi 2024Konular: -
129
New drug introductions and changes in pharmaceutical company payments to breast cancer specialists in Japan, 2016–2019.
Baskı/Yayın Bilgisi 2024Konular: -
130
Payment data to breast cancer specialists from pharmaceutical companies during the study period.
Baskı/Yayın Bilgisi 2024Konular: -
131
-
132
Recording Harms in Behavioural change Intervention Trials (RHABIT) Project Protocol
Baskı/Yayın Bilgisi 2023“…It consists of 4 work packages (WP): WP1 Scoping review of literature to identify definitions, typologies, instruments, and suggested principles for recording harms in behavioural change intervention (BCI) trials; WP2 Qualitative interviews with clinical trials unit (CTU) and NIHR investigators involved in designing and delivering BCI trials; WP3 Workshop(s) to review guidance for recording harms in BCI trials; and WP4 Suggested principles and considerations for harms recording in BCI trials.…”
-
133
Paper-Like Visual Indicator Films for Harmful Hydrophilic Liquids and Vapors
Baskı/Yayın Bilgisi 2021“…Herein, we develop an indicator film that can easily respond to harmful hydrophilic liquids and gases and allow for the visual recognition of a transparency transformation involving hydrated poly(<i>N</i>-isopropylacrylamide). …”
-
134
Paper-Like Visual Indicator Films for Harmful Hydrophilic Liquids and Vapors
Baskı/Yayın Bilgisi 2021“…Herein, we develop an indicator film that can easily respond to harmful hydrophilic liquids and gases and allow for the visual recognition of a transparency transformation involving hydrated poly(<i>N</i>-isopropylacrylamide). …”
-
135
Paper-Like Visual Indicator Films for Harmful Hydrophilic Liquids and Vapors
Baskı/Yayın Bilgisi 2021“…Herein, we develop an indicator film that can easily respond to harmful hydrophilic liquids and gases and allow for the visual recognition of a transparency transformation involving hydrated poly(<i>N</i>-isopropylacrylamide). …”
-
136
-
137
-
138
-
139
-
140